Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.

Item

http://www.wikidata.org/entity/Q38113682

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.

@en

type

Item

label

Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.

@en

prefLabel

Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.

@en

P1476

Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.

@en

P2093

D Elewaut

http://www.w3.org/2001/XMLSchema#string

G Varkas

http://www.w3.org/2001/XMLSchema#string

H Cypers

http://www.w3.org/2001/XMLSchema#string

L Van Praet

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

Unravelling the pathogenesis of inflammatory bowel disease

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

P2888

s00393-012-1114-5

P304

524-529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00393-012-1114-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024527450

http://www.w3.org/2001/XMLSchema#string

P698

23756592

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases